MANNITOL injection, solution

国: アメリカ合衆国

言語: 英語

ソース: NLM (National Library of Medicine)

有効成分:

Mannitol (UNII: 3OWL53L36A) (Mannitol - UNII:3OWL53L36A)

から入手可能:

Henry Schein, Inc.

投与経路:

INTRAVENOUS

処方タイプ:

PRESCRIPTION DRUG

適応症:

Mannitol Injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema. - elevated intraocular pressure. Mannitol Injection is contraindicated in patients with: - Known hypersensitivity to mannitol [see WARNINGS AND PRECAUTIONS (5.1)]. - Anuria [see WARNINGS AND PRECAUTIONS (5.2)]. - Severe hypovolemia [see WARNINGS AND PRECAUTIONS (5.4)]. - Pre-existing severe pulmonary vascular congestion or pulmonary edema [see WARNINGS AND PRECAUTIONS (5.5)]. - Active intracranial bleeding except during craniotomy. 8.1 Pregnancy Risk Summary The available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see DATA).No adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes i

製品概要:

Mannitol Injection 25%, USP is available as 12.5 g/50 mL (0.25 g/mL) of mannitol in a single-dose vial. Supplied as a tray of 25 vials (NDC 0409-4031-01). Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing.

認証ステータス:

New Drug Application

製品の特徴

MANNITOL- MANNITOL INJECTION, SOLUTION
HENRY SCHEIN, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTSOF PRESCRIBING INFORMATIONTHESE HIGHLIGHTS DO NOT INCLUDE
ALL THE
INFORMATION NEEDED TO USE MANNITOL INJECTION SAFELY AND EFFECTIVELY.
SEE FULL PRESCRIBING
INFORMATION FOR MANNITOL INJECTION.MANNITOL INJECTION, FOR INTRAVENOUS
USE
INITIAL U.S. APPROVAL: 1964
RECENT MAJOR CHANGES
Indications and Usage (removed, revised) (1)
03/2020
Contraindications (4)
03/2020
Warnings and Precautions (5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7)
03/2020
INDICATIONS AND USAGE
Mannitol Injection is an osmotic diuretic, indicated for the reduction
of: (2)
intracranial pressure and treatment of cerebral edema. (1)
elevated intraocular pressure. (1)
DOSAGE AND ADMINISTRATION
Administration Instructions (2.1): (3)
For intravenous infusion, preferably through a central venous
catheter.
Prior to administration, evaluate renal, cardiac and pulmonary status
and correct fluid and electrolyte
imbalances.
Recommended Dosage (2.2): (3)
The dosage, concentration and rate of administration depend on the
age, weight and condition of the
patient, including fluid requirement, urinary output and concomitant
therapy.
Reduction of Intracranial Pressure and Treatment of Cerebral Edema:
0.25 g/kg administered every 6 to 8
hours as an intravenous infusion over at least 30 minutes.
Reduction of Intraocular Pressure: 1.5 to 2 g/kg administered as a
single dose intravenously over at least
30 minutes. Administer 60 to 90 minutes before surgery to achieve
maximal effect. (3)
DOSAGE FORMS AND STRENGTHS
Mannitol Injection 25%, USP: 12.5 g/50 mL (0.25 g/mL) in a single-dose
vial (3) (4)
CONTRAINDICATIONS
Known hypersensitivity to mannitol. (4, 5.1)
Anuria. (4, 5.2)
Severe hypovolemia. (4, 5.4)
Pre-existing severe pulmonary vascular congestion or pulmonary edema.
(4, 5.5)
Active intracranial bleeding except during craniotomy. (4)
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions, Including Anaphylaxis: Stop infusion
immediately if hypersensitivity reactio